Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-018852
Filing Date
2025-02-12
Accepted
2025-02-12 16:15:38
Documents
130
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 20-F asnd-20241231.htm   iXBRL 20-F 6364681
2 EX-2.3 asnd-ex2_3.htm EX-2.3 224264
3 EX-4.23 asnd-ex4_23.htm EX-4.23 449447
4 EX-4.24 asnd-ex4_24.htm EX-4.24 545769
5 EX-4.25 asnd-ex4_25.htm EX-4.25 27272
6 EX-4.2(B) asnd-ex4_2b.htm EX-4.2(B) 6483
7 EX-8.1 asnd-ex8_1.htm EX-8.1 18975
8 EX-11.1 asnd-ex11_1.htm EX-11.1 127927
9 EX-12.1 asnd-ex12_1.htm EX-12.1 11480
10 EX-12.2 asnd-ex12_2.htm EX-12.2 11475
11 EX-13.1 asnd-ex13_1.htm EX-13.1 6935
12 EX-13.2 asnd-ex13_2.htm EX-13.2 6964
13 EX-15.1 asnd-ex15_1.htm EX-15.1 3342
14 GRAPHIC img62010886_0.jpg GRAPHIC 11093
15 GRAPHIC img80190973_0.jpg GRAPHIC 441871
16 GRAPHIC img80190973_1.jpg GRAPHIC 84245
17 GRAPHIC img148586500_0.jpg GRAPHIC 72750
18 GRAPHIC img148586500_1.jpg GRAPHIC 386397
19 GRAPHIC img148586500_2.jpg GRAPHIC 96521
20 GRAPHIC img148586500_3.jpg GRAPHIC 58632
21 GRAPHIC img148586500_4.jpg GRAPHIC 68861
22 GRAPHIC img148586500_5.jpg GRAPHIC 192260
23 GRAPHIC img148586500_6.jpg GRAPHIC 237070
24 GRAPHIC img148586500_7.jpg GRAPHIC 128430
25 GRAPHIC img148586500_8.jpg GRAPHIC 61198
26 GRAPHIC img148586500_9.jpg GRAPHIC 2510
  Complete submission text file 0000950170-25-018852.txt   26470539

Data Files

Seq Description Document Type Size
27 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT asnd-20241231.xsd EX-101.SCH 2199716
132 EXTRACTED XBRL INSTANCE DOCUMENT asnd-20241231_htm.xml XML 4595314
Mailing Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900
Business Address TUBORG BOULEVARD 12 HELLERUP G7 DK-2900 45 70 22 22 44
Ascendis Pharma A/S (Filer) CIK: 0001612042 (see all company filings)

EIN.: 000000000 | State of Incorp.: G7 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-36815 | Film No.: 25615027
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)